510(k) K203276

Bead Block (100 - 300µm, 1ml), Bead Block (300 - 500µm, 1ml), Bead Block (500 - 700µm, 1ml), Bead Block (700 - 900µm, 1ml), Bead Block (900 - 1200µm, 1ml), Bead Block (100 - 300µm, 2ml), Bead Block (300 - 500µm, 2ml), Bead Block (500 - 700µm, 2ml), Bead Block (700 - 900µm, 2ml), Bead Block (900 - 1200µm, 2ml) by Biocompatibles UK Ltd (Part of Boston Scientific Corporation — Product Code NOY

K203276 is an FDA 510(k) premarket notification submitted by Biocompatibles UK Ltd (Part of Boston Scientific Corporation for the device "Bead Block (100 - 300µm, 1ml), Bead Block (300 - 500µm, 1ml), Bead Block (500 - 700µm, 1ml), Bead Block (700 - 900µm, 1ml), Bead Block (900 - 1200µm, 1ml), Bead Block (100 - 300µm, 2ml), Bead Block (300 - 500µm, 2ml), Bead Block (500 - 700µm, 2ml), Bead Block (700 - 900µm, 2ml), Bead Block (900 - 1200µm, 2ml)". The FDA issued a decision of Substantially Equivalent on April 20, 2021. The device falls under product code NOY (Agents, Embolic, For Treatment Of Benign Prostatic Hyperplasia), a Class II device regulated under 21 CFR 876.5550.

Clearance Details

Decision
SESE (Substantially Equivalent)
Decision Date
April 20, 2021
Date Received
November 6, 2020
Clearance Type
Traditional
Expedited Review
No
Third Party Review
No

Device Classification

Device Name
Agents, Embolic, For Treatment Of Benign Prostatic Hyperplasia
Device Class
Class II
Regulation Number
876.5550
Review Panel
GU
Submission Type

The device comprises one or more objects placed in a blood vessel to permanently obstruct blood flow to the prostate to treat benign prostatic hyperplasia (BPH).